The United Kingdom and the United States have reached a key trade agreement that will guarantee no duties on UK medicine exports being sold in the US market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to increase spending on pharmaceuticals through the National Health Service (NHS). This commitment ensures that tariffs on these vital exports will remain at nothing for a period of 36 months.
This agreement is in response to earlier warnings to hike duties on patented drug products, with increases mentioned up to double the cost.
"This agreement between the United Kingdom reinforces the global environment for innovative medicines and establishes much-needed fairness to transatlantic pharmaceutical trade," an announcement said.
Economic Impact
Medicines constitute one of the the United Kingdom's largest exports to the United States, which is clearly the largest destination for large UK drugmakers.
Export figures indicate that in the 12 months to the end of last September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This value made up nearly one-fifth of all goods exports in that timeframe.
"This deal secures jobs, stimulates capital expenditure and paves the way for the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary stated.
Specific British Pledges
The pact involves several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to raise overall NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to stay within budget will be restricted at 15%. Last year, repayments exceeded 20%.
Industry Background
The pact comes amid a ongoing dispute between the sector and the ministers over drug pricing and approval rates.
These tensions were heightened by assertions that US patients were paying a premium for the equivalent treatments than patients in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar investments have been directed toward US facilities.
One official stated that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had decreased as a proportion of its resources over the previous ten-year period.
